Andere Sprachen ADC Therapeutics SA

Aktien

A2PSR8

CH0499880968

ADCT

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 10.05.2024			% 5 Tage	% 1. Jan.
4.3 ^USD	-5.91%		-9.09%	+159.04%

07.05.	ADC THERAPEUTICS SA : HC Wainwright bekräftigt seine Kaufempfehlung	ZM
06.05.	Hoffnung auf Zinssenkung beflügelt börsengehandelte Fonds und Aktienfutures vor dem Glockenschlag am Montag	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference	09.05.
Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday	06.05.
ADC Therapeutics : 1Q 2024 Earnings Call	06.05.
ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell	06.05.
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants	06.05.
ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial	06.05.
ADC Therapeutics SA Reports Earnings Results for the First Quarter Ended March 31, 2024	06.05.
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	06.05.
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma	06.05.
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma	06.05.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan	01.05.
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024	01.05.
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed, Refractory B-cell Non-Hodgkin Lymphoma	05.04.
Sector Update: Health Care Stocks Slump Late Afternoon	04.04.
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial	04.04.
Borsa svizzera chiude in rialzo, SMI +0,64%	04.04.
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	04.04.
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024	03.04.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan	01.04.
Chiome Bioscience Cancels License Agreements with ADC Therapeutics	01.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen ADC Therapeutics SA

Aktien

A2PSR8

CH0499880968

ADCT

Andere Sprachen

Filter